Vatalanib succinate
CAS: 212142-18-2
Ref. 3D-MIA14218
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire | ||
| 250mg | To inquire |
Product Information
- 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)
- Butanedioic acid, compd. with N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine (1:1)
- Cgp 79787D
- N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine butanedioate
- N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine butanedioate (1:1)
- Ptk 787
- Ptk 787/Zk 222584
- Ptk 787Zk22258
- Zk 222584
Vatalanib succinate is a small molecule drug that inhibits the activity of the vascular endothelial growth factor receptor (VEGFR). Vatalanib succinate binds to the VEGFR and prevents it from binding to its ligands, such as stem cell factor. It has been shown to inhibit metastatic colorectal cancer in animal models. Vatalanib succinate also has biological effects on other cancer cells, including HL-60 cells and mcf-7 cells. The combination of vatalanib succinate with other compounds, such as colony-stimulating factors or toll-like receptor antagonists, may have synergistic effects.
Chemical properties
Technical inquiry about: 3D-MIA14218 Vatalanib succinate
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
